News
VNRX
1.360
-2.16%
-0.030
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 8h ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at VNRX last week (0601-0605)?
Weekly Report · 1d ago
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
Benzinga · 4d ago
VolitionRx files patent covering Nu.Q technology for Ebola triage
TipRanks · 6d ago
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
PR Newswire · 6d ago
Weekly Report: what happened at VNRX last week (0525-0529)?
Weekly Report · 06/01 09:22
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
PR Newswire · 05/27 12:17
Weekly Report: what happened at VNRX last week (0518-0522)?
Weekly Report · 05/25 09:23
VolitionRx Secures Waiver on Convertible Note Covenant Breach
TipRanks · 05/22 23:15
VolitionRX Earnings Call Balances Breakthroughs and Risks
TipRanks · 05/20 05:12
Analyst Lifts VolitionRx Price Target to $24 on Under-Recognized Nu.Q Platform and Expanding Clinical Applications
TipRanks · 05/19 08:36
Weekly Report: what happened at VNRX last week (0511-0515)?
Weekly Report · 05/18 09:23
VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk
TipRanks · 05/16 00:07
VolitionRx Announces Board Streamlining as Director Departs
TipRanks · 05/15 22:55
VolitionRx anticipates first DETECSEPS patient in September as Q1 revenue rises to about $1M
Seeking Alpha · 05/15 19:31
Full Transcript: VolitionRX Q1 2026 Earnings Call
Benzinga · 05/15 13:46
VolitionRX GAAP EPS of -$0.97 misses by $0.26, revenue of $0.99M beats by $0.46M
Seeking Alpha · 05/15 13:04
VolitionRx reports Q1 revenue $1M, consensus $409,920
TipRanks · 05/14 21:21
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.